ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 With Cyclotron Produced 68Ga Utilizing the QUANTM Irradiation System™ and Solid Targets
19.1.2021 16:00:00 EET | Business Wire | Press release
ARTMS Inc. (ARTMS) and Isotopia Molecular Imaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005044/en/
The specially designed Prostate-Specific Membrane Antigen (PSMA) kit for the preparation of 68Ga-PSMA-11 (a radiopharmaceutical targeting PSMA for the imaging of prostate cancer using Positron Emission Tomography (PET)) was radiolabeled with high activity cyclotron produced 68Ga following irradiation times of less than two hours. The Isotopia kit was radiolabeled with between 500 mCi and just over 2900 mCi of 68Ga following multiple successful 68Ga production runs utilizing the QIS™ and ARTMS’ high performance 68Zn solid targets. The resultant product demonstrated 6-hour stability and radiochemical purity, which met or exceeded all regulatory standards. Cyclotron produced 68Ga combined with a kit solution will give radiopharmacies near unlimited access to this diagnostic product and a cost effective solution.
“The demand for 68Ga radiolabeled products will soon exceed the supply coming from 68Ge/68Ga generators. ARTMS’ QUANTM Irradiation System™ (QIS™) allows for the high activity and high quality 68Ga production the Molecular Imaging community requires to properly serve their patients. The QIS™’ multiple-curie per hour 68Ga production is one of the few true game changers I have seen during my career in Nuclear Medicine. We are very excited to bring on-demand 68Ga doses to clinicians and patients in collaboration with our partners,” says Charles S. Conroy, Chief Executive Officer of ARTMS.
“Isotopia is focused on developing diagnostic and therapeutic tools that best serve our patients. We see 68Ga as a better diagnostic tool to pair with Lu177 treatments. Isotopia’s high activity PSMA “kit” is a major step forward in how the global imaging community diagnoses prostate cancer. Multi-dose vial preparation will allow pharmacies to provide unit doses and allow clinicians to image patients with little to no restrictions. In addition, a 5 minute preparation and more than 95% radiochemical purity will enhance efficiency and save the radiopharmacies time and money. We aim to keep introducing to the market kit-based solutions for 50 and 100mCi Generators, cyclotron produced 68Ga, and Lu177 labeling,” says Dr. Eli Shalom, CEO of Isotopia Molecular Imaging.
ARTMS recently announced the approval for its cyclotron produced 99mTc product by Health Canada. ARTMS will continue the development of cyclotron-based products including 68Ga with a focus on optimizing production potential and satisfying regulatory requirements for use in radiopharmaceutical kits.
About Prostate Cancer
Prostate cancer is the fourth most common cancer worldwide. In 2018, 1.3 million men were diagnosed with prostate cancer for the first time. Despite advances in treatments, prostate cancer still accounts for a significant number of deaths. In 2018, more than 365,000 men died from the disease. Rates of diagnosis are increasing, and the highest levels of prostate cancer are found in the US, Europe, Australia, and New Zealand.
About ARTMS
Based in Vancouver, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System™ (QIS™), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.
For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter @Quantm99 and LinkedIn and visit http://www.artms.ca/.
About Isotopia
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and some of Israel's leading scientists in the field of radiopharmaceuticals. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers, and physicists. The experienced Isotopia team, together with its radio-nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing, are a well-established platform for development. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.
For more information on Isotopia, please visit www.isotopia.co.il.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005044/en/
Contact information
ARTMS Corporate
Charles S. Conroy R.Ph, MBA
ARTMS, Inc.
Chief Executive Officer
conroy@artms.ca
ARTMS Business
Doug Gentilcore
ARTMS, Inc.
Chief Commercial Officer
gentilcore@artms.ca
Isotopia Corporate
Dr. Eli Shalom, PhD
Isotopia Molecular Imaging Limited
Chief Executive Officer
EShalom@isotopia.co.il
Isotopia Business
Keren Moshkoviz
Isotopia Molecular Imaging Limited
Director of Business Development
KMoshkoviz@isotopia.co.il
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esentia Announces Successful Pricing of 6.125% Senior Notes Due 2033 and 6.500% Senior Notes Due 20388.5.2026 04:24:00 EEST | Press release
Esentia Energy Development, S.A.B. de C.V. (“ESENTIA” or the “Company”), today announced the pricing of U.S.$1,000,000,000.00 aggregate principal amount of its 6.125% Senior Notes due 2033 (the “2033 Notes”) and U.S$1,000,000,000.00 aggregate principal amount of its 6.500% Senior Notes due 2038 (the “2038 Notes” and, together with the 2033 Notes, the “Notes”) to be issued by the Company in a private offering to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in accordance with Regulation S under the Securities Act. The 2033 Notes will be issued at a price of 99.517%, and the 2038 Notes will be issued at a price of 98.444%. The 2033 Notes mature on July 30, 2033, and the 2038 Notes mature on July 30, 2038, and will be fully and unconditionally guaranteed by certain of the Company's subsidiaries. The settlement of the Notes is expected to take place on May 14
83% of Restaurants Are Invisible in AI Search: New Uberall Report Reveals the Discovery Gap Reshaping the Quick Service Restaurant Industry7.5.2026 20:35:00 EEST | Press release
Uberall, the global leader in location marketing technology, today released Fast Food, Faster Discovery: The 2026 GEO Playbook for Multi-Location QSRs — the industry’s first benchmark report measuring how AI assistants recommend restaurants and how multi-location QSR (Quick-Service Restaurant) brands can adapt their local marketing strategies for AI-mediated search. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507962493/en/ Fast Food, Faster Discovery: Why AI Is the New Drive-Thru The report draws on Uberall’s proprietary GEO Studio benchmark data and aggregated performance metrics from its global QSR customer base. Its central finding: as consumer restaurant discovery rapidly shifts from traditional search to AI assistants, the majority of QSR locations are effectively absent from AI-generated recommendations — at the exact moment AI is becoming consumers’ primary discovery channel. This visibility gap arrives as the Q
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi7.5.2026 19:57:00 EEST | Press release
Department of Health—Abu Dhabi (DoH) and ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a joint research programme to study how continuous wearable data can advance preventive health. The collaboration marks the beginning of a long-term partnership to advance Abu Dhabi’s prevention-first, data-driven healthcare agenda, and will initially focus on women’s health and cardiometabolic risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507073495/en/ HE Mansoor Al Mansoori (Left) and Tom Hale (Right) The collaboration builds on Abu Dhabi’s advanced public health infrastructure and longitudinal health data assets, integrating them with ŌURA’s real-time, continuous insights across key health indicators. Together, this creates a strong foundation for understanding health at a population level, enabling the identification of risk factors and supporting a shift from reactive care to more proactive, perso
Rave Sues Apple in Five Countries Over App Store Removal7.5.2026 18:03:00 EEST | Press release
Rave Inc. (“Rave” or the “Company”), the developer and operator of the Rave app, a cross-platform co-viewing “super app” with more than 225 million downloads, today announced that it has filed antitrust lawsuits against Apple in five countries: the United States, Canada, Brazil, the Netherlands and Russia. The lawsuits challenge Apple’s unilateral and anticompetitive decision to remove Rave from its App Store, thereby distorting competition, reducing consumer choice in co-viewing functionalities and increasing the costs to users of switching between iPhone and competing smartphone devices. Rave operates a social entertainment app that allows users in different locations to watch their favorite videos, movies, and TV shows together in real time across multiple operating systems and devices, including iOS, Android, Windows and macOS, and communicate through chat and voice. Rave alleges that this cross-platform experience threatened Apple’s closed iOS ecosystem, which Apple maintains by l
emnify named a Visionary in the 2026 Gartner ® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide7.5.2026 18:00:00 EEST | Press release
emnify, a global provider of cloud-native IoT connectivity solutions, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507642325/en/ emnify named a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. Get the report As a first-time recognized vendor, emnify believes this recognition reflects its forward-looking approach to IoT connectivity, building a platform designed to anticipate where enterprise needs are heading rather than replicating the connectivity models of the past. "We feel being named a Visionary in our first appearance in the Gartner® Magic Quadrant™ recognizes our deliberate strategy of the last decade: from owning our core network and pioneering satellite-cellular convergence on a single SIM, to embedding fine-tuned AI models
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom